Adaptive Biotechnologies Corp vs Western Digital Corp — how do they compare? Adaptive Biotechnologies Corp trades at $25.05 (market cap $4.04B), while Western Digital Corp trades at $456.71 (market cap $150.95B). The key difference: Western Digital Corp is far larger — about 37.4× Adaptive Biotechnologies Corp's market cap, and Western Digital Corp pays a 0.14% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | WDC | |
|---|---|---|
Market Cap | $4.04B | $150.95B |
Sector | Health | Technology |
52-Week High | $25.45 | $746.23 |
52-Week Low | $12.30 | $74.66 |
Enterprise Value | $4.10B | $150.42B |
Dividend Yield | — | 0.14% |
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Western Digital (WDC) trades at $438.12, up 0.88% on the day, with strong recent earnings performance beating expectations for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 72.95% net income margin and 131.02% ROE. Recent news highlights AI-driven storage demand as a key growth catalyst, though the stock faces valuation concerns after recent sell-offs.
The outlook remains positive with 72% analyst buy ratings and $665 consensus price target, representing 52% upside potential. Key risks include stretched valuation metrics (P/E 18.04, EV/EBITDA 30.24) and competitive threats from SSD adoption. The company's strong AI storage positioning and margin expansion provide growth opportunities, but investors should monitor execution against high expectations.
Trailing returns across standard periods
Latest headlines on both assets
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →